指南与共识肝病

美国胃肠病学会临床实践更新:肝硬化患者急性肾损伤评估与管理的专家综述

AGA Clinical Practice Update on the Evaluation and Management of Acute Kidney Injury in Patients With Cirrhosis: Expert Review.
指南 / 共识 · Clin Gastroenterol Hepatol · 2022-09-06

美国胃肠病学会(AGA)发布的临床实践更新,基于现有文献和专家意见提出14条最佳实践建议,涵盖肝硬化患者急性肾损伤(AKI)的诊断标准、预防措施、病因排查、感染筛查、药物调整、白蛋白及血管活性药物使用、特利加压素剂量方案、肾脏替代治疗指征及肝移植地位。该文件未进行正式系统评价,建议不附带证据质量或推荐强度分级。

要点

  • AKI诊断标准:48小时内血清肌酐升高≥0.3 mg/dL,或较基线升高≥50%,或尿量<0.5 mL/kg/h持续>6小时。
  • 所有AKI患者均需排查感染,行诊断性腹腔穿刺、血尿培养及胸部X线;不推荐常规预防性抗生素。
  • 特利加压素起始1 mg每4-6小时静脉推注,第3天肌酐未降≥25%可增至最大2 mg每4-6小时;FDA限制肌酐≥5 mg/dL或氧饱和度<90%者禁用。

核心结论

  • 该专家综述为肝硬化合并AKI患者的评估与管理提供实践建议,强调病因鉴别、感染筛查、药物调整及分阶梯治疗。
  • 建议不附带正式的证据质量或推荐强度分级。

研究设计与样本

  • 美国胃肠病学会(AGA)研究所临床实践更新,基于已发表文献和专家意见制定,未进行正式系统评价。
  • 由AGA临床实践更新委员会和AGA理事会委托并批准,经内部同行评议和《Clinical Gastroenterology & Hepatology》标准外部同行评议。

主要发现

  • AKI病因包括低血容量(容量反应性,肝硬化患者最常见原因)、急性肾小管坏死、肝肾综合征伴AKI(HRS-AKI,容量复苏后仍持续的功能性肾衰竭)、HRS伴急性肾病(病程<3个月且不符合HRS-AKI标准)及肾后性(罕见)。
  • 特利加压素相关缺血性副作用包括心绞痛及手指、皮肤和肠道缺血,从最低剂量起始并逐渐上调可降低风险。
  • 过度使用白蛋白存在肺水肿风险,需密切监测液体状态。

关键数值与推荐

  • AKI诊断:48小时内血清肌酐升高≥0.3 mg/dL,或较基线升高≥50%,或尿量<0.5 mL/kg/h持续>6小时。
  • 预防措施:避免肾毒性药物如非甾体抗炎药;避免过度或未监测的利尿剂或非选择性β受体阻滞剂;避免大量放腹水不补充白蛋白;劝告患者戒酒。
  • 当肌酐较基线翻倍时,给予白蛋白1 g/kg/d共2天;若肌酐仍高于基线两倍,启动HRS-AKI治疗:第1天白蛋白1 g/kg静脉注射,随后每日20-40 g,联合血管活性药物(特利加压素;若不可及,根据机构偏好选用奥曲肽联合米多君或去甲肾上腺素),持续至肌酐恢复至≤0.3 mg/dL基线内连续2天后的24小时或总疗程14天。
  • 特利加压素推注:1 mg每4-6小时(每日总量4-6 mg);第3天肌酐较基线未降至少25%时增至最大2 mg每4-6小时(每日总量8-12 mg);或持续静脉输注起始2 mg/d,每24-48小时逐渐上调至最大12 mg/d。FDA限制:肌酐≥5 mg/dL或氧饱和度<90%者禁用。
  • 米多君口服起始7.5 mg,上调至12.5 mg每日3次,联合奥曲肽起始100 μg上调至200 μg皮下注射每日3次;去甲肾上腺素持续静脉输注起始0.5 mg/h,每4小时增加0.5 mg/h至最大3 mg/h,目标平均动脉压升高≥10 mm Hg和/或尿量>50 mL/h至少4小时。

临床怎么用

  • 所有AKI患者需严格排查感染,行诊断性腹腔穿刺评估自发性细菌性腹膜炎,并行血尿培养及胸部X线;不推荐常规预防性抗生素,强烈怀疑感染时启动广谱抗生素。
  • AKI诊断后应停用利尿剂和非选择性β受体阻滞剂,停用非甾体抗炎药,治疗诱发因素并补充液体丢失;监测尿量、生命体征,必要时行超声心动图或中心静脉压监测(已有中心静脉导管时)。
  • 特利加压素和去甲肾上腺素从最低剂量起始并逐渐上调以降低缺血性副作用风险;密切监测液体状态以防范白蛋白过量所致肺水肿。

局限性

  • 本文未进行正式系统评价,建议不附带正式的证据质量或推荐强度分级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DESCRIPTION: The purpose of this American Gastroenterological Association (AGA) Institute Clinical Practice Update is to review the available published evidence and expert advice regarding the clinical management of patients with suspected acute kidney injury in patients with cirrhosis. METHODS: This article provides practical advice for the management of patients with cirrhosis and acute kidney injury based on the best available published evidence. This best practice document is not based on a formal systematic review. This expert review was commissioned and approved by the AGA Institute Clinical Practice Updates Committee and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership and underwent internal peer review by the Clinical Practice Updates Committee and external peer review through the standard procedures of Clinical Gastroenterology & Hepatology. These Best Practice Advice (BPA) statements were drawn from a review of the published literature and from expert opinion. Since systematic reviews were not performed, these BPA statements do not carry formal ratings of the quality of evidence or strength of the presented considerations. BEST PRACTICE ADVICE 1: Acute kidney injury (AKI) should be diagnosed when the serum creatinine increases by ≥0.3 mg/dL within 48 hours or is ≥50% from baseline or when the urine output is reduced below 0.5 mL/kg/h for >6 hours. BEST PRACTICE ADVICE 2: Preventive measures against the development of AKI in cirrhosis include (1) avoidance of potentially nephrotoxic medications like nonsteroidal anti-inflammatory drugs (NSAIDs), (2) avoidance of excessive or unmonitored diuretics or nonselective beta-blockade, (3) avoidance of large-volume paracentesis without albumin replacement, and (4) counseling patients to avoid alcohol use. BEST PRACTICE ADVICE 3: (A) Investigation is directed to determining the cause of AKI, which can be due to hypovolemic causes (volume responsive, and the most common cause of AKI in patients with cirrhosis); acute tubular necrosis; hepatorenal syndrome with AKI (HRS-AKI) (a functional renal failure that persists despite volume repletion); HRS with acute kidney disease, a type of functional renal failure of <3 months- duration in which criteria for HRS-AKI are not met; or postrenal, which occurs only rarely. (B) The specific type of AKI should be identified through a careful history, physical examination, blood biochemistry, urine microscopic examination, urine chemistry (Na+ and urea) and selected urinary biomarkers, and renal ultrasound. BEST PRACTICE ADVICE 4: A rigorous search for infection is required in all patients with AKI. A diagnostic paracentesis should be carried out to evaluate for spontaneous bacterial peritonitis; blood and urine cultures and chest radiograph are also required. There is no role for routine prophylactic antibiotics in patients with AKI, but broad-spectrum antibiotics should be started whenever infection is strongly suspected. BEST PRACTICE ADVICE 5: When AKI is diagnosed, diuretics and nonselective beta-blockers should be held, NSAIDs discontinued, the precipitating cause of AKI treated, and fluid losses replaced, administering albumin 1 g/kg/d for 2 days if the serum creatinine shows doubling from baseline. Urine output, vital signs, and when indicated, echocardiography or CVP (if there is a pre-existing central line) should be used to monitor fluid status. BEST PRACTICE ADVICE 6: When the serum creatinine remains higher than twice the baseline value despite these measures, treatment of HRS-AKI should be initiated with albumin at a dose of 1 g/kg intravenously on day 1 followed by 20-40 g daily along with vasoactive agents (terlipressin; if terlipressin is not available, either a combination of octreotide and midodrine; or norepinephrine, depending on institutional preferences) and continued either until 24 hours following the return of the serum creatinine level to within ≤0.3 mg/dL of baseline for 2 consecutive days or for a total of 14 days of therapy. BEST PRACTICE ADVICE 7: Terlipressin should be initiated as a bolus dose of 1 mg every 4-6 hours (total 4-6 mg/d). The dose should be increased to a maximum of 2 mg every 4-6 hours (total 8-12 mg/d) if there is no reduction in serum creatinine at day 3 of therapy by at least 25% compared to the baseline value. Alternatively, clinicians can administer terlipressin by continuous intravenous infusion at a lower starting dose of 2 mg/d, which may reduce ischemic side effects and increase the dose gradually every 24-48 hours up to a maximum dose of 12 mg/d, or reversal of HRS. As per Food and Drug Administration restrictions, terlipressin should not be used in patients with a serum creatinine ≥5 mg/dL, or oxygen saturation of <90%. BEST PRACTICE ADVICE 8: Oral midodrine when used should be initiated at doses of 7.5 mg and titrated upward to 12.5 mg 3 times daily with octreotide (starting with 100 μg and titrating upward to 200 μg subcutaneously 3 times daily). BEST PRACTICE ADVICE 9: Norepinephrine should be used as a continuous intravenous infusion at a starting dose of 0.5 mg/h and the dose increased every 4 hours by 0.5 mg/h to a maximum of 3 mg/h with the goal of increasing the mean arterial pressure by ≥10 mm Hg and/or the urine output to >50 mL/h for at least 4 hours. BEST PRACTICE ADVICE 10: The risks of ischemic side effects of terlipressin and norepinephrine include angina and ischemia of fingers, skin, and intestine. These side effects may be lowered by starting at the lowest dose and gradually titrating upward. BEST PRACTICE ADVICE 11: Fluid status should be closely monitored because of the risk of pulmonary edema with excessive use of albumin. BEST PRACTICE ADVICE 12: Renal replacement therapy (RRT) may be used in the management of (A) AKI secondary to acute tubular necrosis; (B) HRS-AKI in potential candidates for liver transplantation (that is, RRT should not be used in patients with HRS-AKI who are not candidates for liver transplantation); and (C) AKI of uncertain etiology in which the need for RRT may be considered on an individual basis. BEST PRACTICE ADVICE 13: Transjugular intrahepatic portosystemic shunts should not be used as a specific treatment of HRS-AKI. BEST PRACTICE ADVICE 14: Liver transplantation is the most effective treatment for HRS-AKI. Pharmacotherapy for HRS-AKI before proceeding with liver transplantation may be associated with better post-liver transplantation outcomes. Selected patients with HRS-AKI may require simultaneous liver kidney transplantation based on updated Organ Procurement and Transplantation Network listing criteria.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Flamm SL, Wong F, Ahn J, et al. AGA Clinical Practice Update on the Evaluation and Management of Acute Kidney Injury in Patients With Cirrhosis: Expert Review. Clin Gastroenterol Hepatol. 2022. PMID: 36075500. doi:10.1016/j.cgh.2022.08.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。